These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37857434)

  • 21. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia.
    Kari MA; Heinonen K; Ikonen RS; Koivisto M; Raivio KO
    Arch Dis Child; 1993 May; 68(5 Spec No):566-9. PubMed ID: 8323356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using dexamethasone wisely in invasively ventilated preterm infants.
    Gentle SJ; Sant'Anna G; Carlo WA
    Pediatr Pulmonol; 2022 Apr; 57(4):785-786. PubMed ID: 34994096
    [No Abstract]   [Full Text] [Related]  

  • 23. Is chronic lung disease (CLD) in premature infants preventable?
    Yeh TF
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1996; 37(4):241-3. PubMed ID: 8854342
    [No Abstract]   [Full Text] [Related]  

  • 24. Response to dexamethasone in ventilated preterm infants: effect of radiographic subtype of chronic lung disease.
    Kothadia JM; O'Shea TM; Auringer ST; Dillard RG
    Am J Perinatol; 1996 Aug; 13(6):377-81. PubMed ID: 8865986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes.
    Cuna A; Lewis T; Dai H; Nyp M; Truog WE
    Pediatr Pulmonol; 2019 Feb; 54(2):165-170. PubMed ID: 30537393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexamethasone and bronchopulmonary dysplasia.
    Frank L; Lecuona PC
    Pediatrics; 1996 Sep; 98(3 Pt 1):514-5. PubMed ID: 8784386
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of dexamethasone on lymphocyte subpopulations in premature infants with bronchopulmonary dysplasia.
    Parimi PS; Birnkrant DJ; Rao LV; Diaz G; Moore JJ
    J Perinatol; 1999; 19(5):347-51. PubMed ID: 10685255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postnatal steroids: the way forward.
    Halliday HL
    Arch Dis Child Fetal Neonatal Ed; 2011 May; 96(3):F158-9. PubMed ID: 21289014
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of dexamethasone on blood pressure in premature infants with bronchopulmonary dysplasia.
    Marinelli KA; Burke GS; Herson VC
    J Pediatr; 1997 Apr; 130(4):594-602. PubMed ID: 9108858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of dexamethasone in premature infants at risk for bronchopulmonary dysplasia or who already have developed chronic lung disease: a cautionary note.
    Frank L
    Pediatrics; 1991 Aug; 88(2):413-6. PubMed ID: 1741827
    [No Abstract]   [Full Text] [Related]  

  • 31. Randomized Trial of 42-Day Compared with 9-Day Courses of Dexamethasone for the Treatment of Evolving Bronchopulmonary Dysplasia in Extremely Preterm Infants.
    Marr BL; Mettelman BB; Bode MM; Gross SJ
    J Pediatr; 2019 Aug; 211():20-26.e1. PubMed ID: 31349916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dexamethasone on blood pressure in premature infants with bronchopulmonary dysplasia.
    Adelman RD
    J Pediatr; 1998 Jan; 132(1):187. PubMed ID: 9470029
    [No Abstract]   [Full Text] [Related]  

  • 33. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm.
    Cheong JL; Burnett AC; Lee KJ; Roberts G; Thompson DK; Wood SJ; Connelly A; Anderson PJ; Doyle LW;
    J Pediatr; 2014 Apr; 164(4):737-743.e1. PubMed ID: 24332820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
    Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD001146. PubMed ID: 34674229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
    Doyle LW; Cheong JL; Hay S; Manley BJ; Halliday HL
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD001145. PubMed ID: 34758507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.
    Onland W; Offringa M; van Kaam A
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD002311. PubMed ID: 36521169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of bone mineral content measurement in preterm infants given corticosteroids for bronchopulmonary dysplasia].
    Tricoire J; Rolland M; Trémollières F; Ribot C
    Arch Pediatr; 1998 Jun; 5(6):697-9. PubMed ID: 9759223
    [No Abstract]   [Full Text] [Related]  

  • 38. Growth and growth factors in premature infants receiving dexamethasone for bronchopulmonary dysplasia.
    Skinner AM; Battin M; Solimano A; Daaboul J; Kitson HF
    Am J Perinatol; 1997 Oct; 14(9):539-46. PubMed ID: 9394163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the plasma aminogram of parenterally fed infants treated with dexamethasone for bronchopulmonary dysplasia.
    Ng PC; Brownlee KG; Kelly EJ; Henderson MJ; Smith M; Dear PR
    Arch Dis Child; 1992 Oct; 67(10 Spec No):1193-5. PubMed ID: 1444557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological adverse effects of early postnatal dexamethasone in very preterm infants.
    Baud O; Zupan V; Lacaze-Masmonteil T; Dehan M
    Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F159. PubMed ID: 10325800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.